Search

Objective: to evaluate the role of Epstein-Barr virus (EBV) on the intestinal mucosa in the evolution of inflammatory bowel disease (IBD). The risk factors for EBV infection and the frequency of EBV-associated lymphoproliferative disorders in IBD patients were also investigated.Methods: intestinal biopsies of IBD patients with available EBV status determined by Epstein-Barr-encoding RNA (EBER) in situ hybridization were identified in the Pathology Database of our center. Clinical information, including phenotypic characteristics of IBD, previous treatments, diagnosis of lymphoma and patient outcome were reviewed in all cases.Results: fifty-six patients with IBD (28 Crohn's disease, 27 ulcerative colitis and one unclassified colitis) were included. EBV in intestinal mucosa was positive in 26 patients (46 %) and was associated to a lymphoproliferative syndrome in one case. EBV positivity was associated with severe histological activity (52 % vs 17.2 %; p 0.007), the presence of a lymphoplasmacytic infiltrate (50 % vs 33.3 %; p 0.03) and active steroid treatment (61.5 % vs 33.3 %; p 0.03). Multi-variate analyses only found an association between EBV and lymphoplasmacytosis (p 0.001). Escalation in previous treatment was significantly more frequent in the EBER+ group (53.8 % vs 26.7 %; p 0.038). No cases developed lymphoma during follow-up.Conclusions: EBV on the intestinal mucosa is associated with a poor outcome of IBD and the need for escalation of therapy. Lymphoplasmacytic infiltrate is associated with EBV infection. EBER+ patients used steroids more frequently compared with EBER- patients. No EBER+ patients developed lymphoma during follow-up.

[Background] Detection of epidermal growth factor receptor (EGFR) mutations in exons 18–21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System., [Methods] EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla)., [Results] The overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%., [Conclusions] The Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy., Supported by each clinical center. Biocartis provided free-of-charge Idylla™ EGFR Mutation Test cartridges.

[Background] Pancreatobiliary maljunction is a rare disease characterized by the junction of the pancreatic and biliary ducts outside of the duodenal wall, which normally results in a large common duct. As a result, there is a greater risk of acute pancreatitis and cancer of the gallbladder and biliary tract., [Case report] We present the case of a 43-year-old female diagnosed with a pancreatobiliary maljunction and an associated stenosis of the bile duct, secondary to an episode of acute pancreatitis. She underwent several endoscopic retrograde cholangiopancreatography procedures over the course of three years, without improvement of the stenosis, and therefore a surgical approach was taken. Prior to the surgical intervention, magnetic resonance imaging showed the presence of an 11-mm polyp in the gallbladder. A histological study of the surgical sample identified intramucosal adenocarcinoma over a tubular adenoma of the gallbladder., [Discussion] Pancreatobiliary maljunction can be considered as a premalignant entity due to the risk of developing cancer of the biliary tree and gallbladder. Therefore, these patients should undergo a prophylactic intervention, despite being asymptomatic.

Introduction: Image and metabolic techniques (CT, PET and EBUS) during the study of lung cancer set the pathway to sampling mediastinal LN using EBUS. Discrimination between benign or malignant nature of LN is complex, because there are inconsistent data on morphological and metabolic expression of NNLN. Findings integration from the diferents techniques may guide the probability of benign nature, direct the sampling method and estabish the priority to mediastinoscopy (MED) Aim: The aim of our study was describe the NNLN profile compared with CT, PET/CT and the EBUS in patient with CP and correlate those findings Methods: Period:January 2012-March 2015. We include 86 LN of 81 patients (31 NNLN and 55 NLN) with LC. All patients dispose TC and PET before EBUS-TBNA. The analyzed variables: CT/PET findings, location and size of primary tumor and LN ultrasound signs of studied LN. All results were confirmed by MED. We analyze and correlate findings in NNLN and neoplastic LN Results: No difference in size, SUV and localization of primary tumor between NNLN and NLN. The mean (x - ) size in NNLN and NLN were 17,97 mm vs 23,64 mm respectively. The x - SUV were 4,05 in NNLN (16,5% with - SUVratio (LN SUV / primary Tu SUV) were 0.46 in NNLN (54,1 with r = -0.43 p=0,03) and positive in NLN (r=0.41, p=0,02). The central hilliar sign was the only benign sign, with low sensivity (28%) Conclusions: The presentation of NNLN in patients with LC is heterogeneous with no correlation between image and metabolic test. Lack of concordance in all techniques is suggestive of a benign nature.

Introduction: The diagnostic profitability of EBUS-TBNA is highly variable between different studies. Failure to identify those factors depending on the technique and the underlying neoplasia which can determine it. Materials and Methods: We included 162 patients with LC between the periods January 2010 to September 2014. The analyzed variables: histology, CT/PET findings, location and size of primary tumor, ultrasound descriptions of mediastinal lymph nodes (LN), technical aspects of EBUS-TBNA. The diagnostic accuracy was expressed as sensitivity, specificity, PPV and NPV.Cervical mediastinoscopy and surgical resection were considered as reference standard. Due the important diagnostic implication of the NPV, we focus on analyze the factors which can condition it. Results: Of the 162 patients included, 153 were NSCLC and 9 SCLC. The prevalence was 72% and NPV 72%. The total of false negative results (FN) was 18 patients . On 7/18 FN, a systematic sampling was not performed. In 4/18 FN, the cytology was reported as not representative of lymphadenopathy (LN), these being predominantly left LN. In 7/18, a FN result was obtained even with adequate sampling and representative cytology. Most of these LN were accessible on the right side and showed ultrasound evidence of necrosis in five of them. In one of those cases the diagnosis was by EUS-TBNA. Conclusions: During EBUS-TBNA, it´s necessary to execute a systematic sampling of all visible LN. The access of left nodes stations could be improved complementing the study with EUS-TBNA. In the absence of ROSE, with ultrasound evidence of necrosis, the LN sampling area should be better selected and / or increase the number of punctures.